Protagenic Therapeutics Delays 10-Q Filing Amid Restructuring

Protagenic Therapeutics ( (PTIX) ) has released a notification of late filing.

Protagenic Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to a restructuring plan approved on August 8, 2025, which involves transitioning to a virtual operating model and modifying certain obligations. This has necessitated additional time for management to finalize related accounting and disclosures, including measuring exit costs and updating risk disclosures. The company expects to file the report by August 19, 2025, within the five-day extension allowed. Protagenic Therapeutics does not anticipate significant changes in its financial results compared to the same period last year. The notification was signed by Alexander K. Arrow, the Chief Financial Officer, indicating ongoing compliance efforts.

Spark’s Take on PTIX Stock

According to Spark, TipRanks’ AI Analyst, PTIX is a Underperform.

Protagenic Therapeutics faces significant financial difficulties, with no revenue and persistent losses. Technical indicators suggest weak market momentum, and the company’s valuation is unattractive due to negative earnings. These factors collectively result in a low overall stock score, reflecting substantial risks and challenges.

To see Spark’s full report on PTIX stock, click here.

More about Protagenic Therapeutics

Average Trading Volume: 1,852,224

Technical Sentiment Signal: Sell

Current Market Cap: $2.39M

See more insights into PTIX stock on TipRanks’ Stock Analysis page.